43 results on '"Engert, Andreas"'
Search Results
2. Behandlung des nodulär Lymphozyten-prädominanten Hodgkin Lymphoms
3. Neue Ansätze zur Behandlung des rezidivierten oder refraktären Hodgkin Lymphoms
4. Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma
5. Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma
6. Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis
7. Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial
8. Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP
9. Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group
10. Therapiealgorithmus für Patienten mit Hodgkin-Lymphom
11. Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group
12. Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG)
13. Lymphocyte predominant cells detect Moraxella catarrhalis-derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma
14. Author Correction: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility
15. Rezidiviertes oder refraktäres klassisches Hodgkin-Lymphom: Neue Therapieansätze
16. Proton versus photon deep inspiration breath hold technique in patients with hodgkin lymphoma and mediastinal radiation: A Planning Comparison Of Deep Inspiration Breath Hold Intensity Modulation Radiotherapy And Intensity Modulated Proton Therapy
17. Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility
18. The GHSG Approach to Treating Hodgkin’s Lymphoma
19. Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL
20. Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma: When should they be considered and which questions remain open?
21. Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci
22. Therapiealgorithmus für Patienten mit Hodgkin-Lymphom
23. Advances in the treatment of Hodgkin lymphoma
24. The Role of Autologous Transplantation in Hodgkin Lymphoma
25. Transnational Hedge Fund Regulation
26. How Does the Market React to the Societas Europaea?
27. Incorporating under European Law: The Societas Europaea as a Vehicle for Legal Arbitrage
28. Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study
29. Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab
30. Nodular lymphocyte-predominant Hodgkin lymphoma
31. Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia
32. Population Pharmacokinetics of the BEACOPP Polychemotherapy Regimen in Hodgkin’s Lymphoma and its Effect on Myelotoxicity
33. Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma
34. Discussion Report
35. First-line treatment of Hodgkin’s lymphoma
36. Nodular lymphocyte-predominant Hodgkin’s lymphoma
37. Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma
38. Recombinant Human Erythropoietin as an Alternative to Blood Transfusion in Cancer-Related Anaemia
39. Antiangiogenese: ein neuer Ansatz in der Tumortherapie?
40. Aktueller Stellenwert der Hochdosistherapie in der Hämatologie und internistischen Onkologie
41. Methotrexat: Pharmakologie, Toxizität und Rescuemaßnahmen bei hochdosierter Behandlung
42. Pathogenese und Therapie des Hodgkin-Lymphoms
43. Non-Hodgkin’s Lymphoma: A Review of Immunotherapeutic Approaches to Treatment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.